Abstract
Background and Aims Elderly patients, especially octogenarians, are underrepresented in recently published studies, that showed a benefit of endovascular stroke treatment (EST) for patients with acute basilar artery occlusion (BAO). We aimed to compare the clinical outcome of octogenarians with BAO and EST compared to younger patients and to identify independent outcome predictors.
Methods This is a retrospective, single-center analysis of patients treated for BAO with EST from 01/2013 until 06/2021 in a tertiary stroke center. Octogenarians (≥ 80 years) were compared to younger patients. Study endpoint was the clinical outcome as per modified Rankin Scale (mRS) 90d after stroke onset. The study groups were compared in univariate analysis and a multivariable logistic regression analysis was performed to define independent predictors for clinical outcome.
Results In this study cohort, 74/191 (38.7 %) octogenarians had a higher pre-stroke mRS (Median, IQR: 2, 1 – 3 octogenarians vs. 0, 0 – 1 younger patients, p < 0.001) and a comparable NIHSS before EST (Median, IQR: 21, 8 – 34 vs. 22, 10 – 38 younger, p = 0.712). They showed a comparable mRS 90d after stroke onset (Median, IQR: 5, 2 – 6 younger vs. 5, 3 – 6 octogenarians, p = 0.194), but less often a good clinical outcome (mRS 0-2: n = 27, 23% younger vs. n = 9, 11.7% octogenarians, p = 0.004). The rate of bad clinical outcome was comparable (mRS 5-6, n = 63, 46.7% younger vs. 39, 50.6 % octogenarians, p = 0.194). Baseline NIHSS was a stable independent predictor for clinical outcome in both study groups (e.g. for bad clinical outcome: in octogenarians OR 1.04, CI 100 – 10.85, p = 0.0019, in younger OR 1.061, CI 1.027-1.098, p = 0.005)
Conclusion Octogenarians with acute BAO eligible for EST are less likely to be functionally independent at 90 days after stroke onset, but the rate of death or severe handicap is comparable to younger patients. The admission NIHSS predicts clinical outcome in both age groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Medical Faculty, University of Heidelberg, Germany, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
matthias.mutke{at}med.uni-heidelberg.de
amandahamburgcity{at}hotmail.com
niclas.schmitt{at}med.uni-heidelberg.de
fatih.seker{at}med.uni-heidelberg.de
min.chen{at}med.uni-heidelberg.de
silvia.schonenberger{at}med.uni-heidelberg.de
markus.moehlenbruch{at}med.uni-heidelberg.de
martin_bendszus{at}med.uni-heidelberg.de
c.weyland{at}ukaachen.de
Jessica.jesser{at}med.uni-heidelberg.de
Data Availability
All data produced in the present study are available upon reasonable request to the authors